Project Grant R43HL172316
Award Date
9/1/24
Completion Date
8/31/25
Dollars Obligated
$605K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $706,806 Project Grant under CFDA 93.837 (Cardiovascular Diseases Research) to Elimu Informatics Inc., a small business software company in California. The grant funds the design, development, and evaluation of TIBSA (Tailored Interoperable Guideline-Based Clinical Decision-Support System for Asthma), a clinical decision support application that incorporates the 2020 NHLBI asthma management guidelines, patient-specific data,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $842,408 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Inspire RX LLC, a start-up company based in Ann Arbor, Michigan. The goal of this 18-month project is to refine and further evaluate Inspire RX's "Aerosolve Biohelmet", a personal negative pressure device capable of preventing the spread of aerosolized pathogens while enabling non-invasive oxygen therapies for patients with highly...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $477,191 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Phrase Health, Inc., a small disadvantaged business located in Philadelphia, PA. The purpose of this 22-month project is to develop a library of "out of the box" quality improvement (QI) templates focused on select lung diseases, including asthma, bronchiolitis, and COPD. The project will involve translating existing QI project templates from...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,107,276 to Lasarrus Clinic And Research Center Inc. to develop a mobile health system for remote monitoring of patients with Chronic Obstructive Pulmonary Disease (COPD). The project aims to enhance patient adherence to remote monitoring and early symptom recognition, in order to reduce COPD readmissions and healthcare costs. The system utilizes a wearable...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $347,608 to Biotherapeutics, Inc. to develop a novel, oral, once-daily, immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) characterize the therapeutic efficacy and route of administration of the drug candidate in mouse models of asthma, and 2) determine the translational ability of the therapeutic...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $288,986 to Biotherapeutics, Inc., a biotechnology company in Blacksburg, VA. The grant supports the development of a novel oral immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) Determine the safety profile and pharmacokinetics of the new therapeutic in rats, and 2) Characterize the therapeutic...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $269,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Steth X Microsystems Inc. to develop a smart, wearable contact microphone patch for extended and remote monitoring of lung functions. The goal is to create a low-profile, battery-powered wireless device capable of accurately detecting and quantifying adventitious lung sounds as well as breathing abnormalities in patients with respiratory...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel oral small molecule therapeutics for the treatment of progressive pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The goal is to create a safer and more effective therapy compared to the currently approved drugs, which only slow disease progression and have significant side effects. Novomedix will...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...
This Project Grant award for $355,935 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports the development of a novel, oral immunoregulatory therapeutic for the treatment of asthma. The primary objectives are to characterize the therapeutic efficacy and dosing regimen of the compound in mouse models of asthma, and to evaluate its ability to modulate immune function and suppress inflammation in human...